Akebia Therapeutics Inc. (AKBA)
NASDAQ
0.5670
+0.0050 (+0.89%)
Closed
Oct 23, 2026
Day's Range
0.56200.5960
52 wk Range
0.54203.20
Financial Statements - AKBA - Akebia Therapeutics Inc.
Revenue
236.19M▲ 47.5%
Net Income
-5.34M▲ 92.3%Net Margin -2.3%
EBITDA
24.82M▲ 293.7%
Free Cash Flow
59.89M▲ 247.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 236.19M | 160.18M | 194.62M | 292.48M | 211.65M | 294.64M |
| Cost of Goods | 39.46M | 63.17M | 74.14M | 85.56M | 150.67M | 296.47M |
| Gross Profit | 196.73M | 97M | 120.47M | 206.91M | 60.97M | -1.83M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 23.49M | -50.41M | -46.07M | -64.84M | -264.50M | -377.82M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -3.04M | -811K | 182K | -13.69M | 2.41M | 1.85M |
| Pre Tax Income | -3.72M | -69.41M | -51.92M | -94.22M | -282.02M | -384.84M |
| Income Tax | 1.62M | - | - | 0 | 0 | 0 |
| Net Income | -5.34M | -69.41M | -51.92M | -94.22M | -282.02M | -384.84M |
| EPS Basic | -0.02 | -0.33 | -0.28 | -0.51 | -1.7 | -2.77 |
| EPS Diluted | -0.02 | -0.33 | -0.28 | -0.51 | -1.7 | -2.77 |
| Basic Shares Outstanding | 257.15M | 210.94M | 187.46M | 182.78M | 165.94M | 138.46M |
| Diluted Shares Outstanding | 257.15M | 210.94M | 187.46M | 182.78M | 165.94M | 138.46M |
| Ebit | 20.45M | -51.22M | -45.89M | -78.53M | -264.50M | -377.82M |
| Ebitda | 24.82M | -12.81M | -7.56M | -24M | -226.53M | -343.13M |
| Net Income Continuous Operations | -5.34M | -69.41M | -51.92M | -94.22M | -282.02M | -384.84M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
